Insulin resistance and progression to type 1 diabetes in the european nicotinamide diabetes intervention trial (ENDIT)

Diabetes Care

Volumn 31, Issue 4, 2008, Pages

  Wilkin, Terence J ^a,b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BODY MASS; CELL DESTRUCTION; CELL LOSS; DISEASE COURSE; FOLLOW UP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; ONSET AGE; PANCREAS ISLET BETA CELL; RISK FACTOR; EUROPE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; MALE; NOTE;

DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; EUROPE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; RISK FACTORS;

EID: 48649091528     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc07-2202     Document Type: Letter

References (5)

1. Wilkin TJ: The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 44:914-922, 2001
2. Bingley PJ, Mahon JL, Gale EA, the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 31: 146-150, 2007
3. Wilkin TJ: The accelerator hypothesis cannot be tested using the type 2 diabetes gene, TCF7L2. Diabetologia 50:1780, 2007
4. WilkinTJ: Testingthe accelerator hypothesis: body size, β-cell function, and age at onset of type 1 (autoimmune) diabetes- (Letter). Diabetes Care 29:1462-1464, 2006
5. Wilkin TJ: To boldly go-or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571-1575, 2007